Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 41.75B | 58x | CHF 578.60 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | ||
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 41.75B | 58x | CHF 578.60 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | ||
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 4.39B | 36.6x | 5.1 | CHF 58.55 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 2.03B | 27x | 0.2 | CHF 36.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 2.03B | 26.9x | 0.2 | CHF 36.95 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.6% Upside | Upgrade to Pro+ | |
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 804.03M | -69.5x | -3 | CHF 21.20 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 575.56M | 7.4x | 0.01 | CHF 47.40 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.9% Upside | Upgrade to Pro+ | |
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 232.16M | -0.9x | -0.07 | CHF 1.25 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.9% Downside | Upgrade to Pro+ | |
Bioversys Ag | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 204.34M | CHF 36.17 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 193.60M | -10x | 0.67 | CHF 9.60 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 155.98M | -2.2x | 0.68 | CHF 4.24 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 108.52M | 11.8x | 0.29 | CHF 17.85 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 38.50M | -0.4x | CHF 3.07 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 6.39M | 1.2x | -0 | CHF 0.06 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |